Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv
Strengthens investment in channels of the future to expand patient reach
Strengthens investment in channels of the future to expand patient reach
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
Expanding diagnostics footprint in East India
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Subscribe To Our Newsletter & Stay Updated